Abstract
Hybridoma technology, which allows the production of monoclonal antibodies, is one of the cornerstones of modern molecular biology and biotechnology. New techniques for the rapid production of specific portions of antibody molecules, however, may soon replace hybridomas in many applications. One such technique has been developed by Richard A. Lerner, director of the Research Institute of Scripps Clinic, La Jolla, Calif., and Stephen J. Benkovic, a chemistry professor at Pennsylvania State University, University Park, and coworkers (C&EN, Dec. 11, 1989, page 5). The procedure enables the scientists to generate and rapidly screen very large numbers of what are known as Fab fragments. A Fab contains those pieces of an antibody protein that are responsible for binding antigen. Another hybridoma alternative was developed by Greg Winter and coworkers at the U.K. Medical Research Council's Laboratory of Molecular Biology, Cambridge (C&EN, Nov. 20, 1989, page 15). Winter's ultimate goal is production of something...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
